DIAGNOS Advances Regulatory Strategy for CARA in Key Markets: Updates on Health Canada, FDA, and SFDA Progress

Executive Summary

• DIAGNOS submitted its AI‑based eye‑health platform CARA for marketing approval to Saudi Arabia’s SFDA.
• The company is on track to file a formal Health Canada application for CARA within the current quarter.
• FDA meetings clarified requirements for 510(k) clearance, positioning CARA for U.S. market entry.

Key Details

• Saudi Arabia (SFDA): Formal submission of CARA completed; awaiting marketing approval.
• Canada (Health Canada): Active engagement with regulator; formal application expected to be filed this quarter.
• United States (FDA): Strategic meetings identified specific 510(k) clearance requirements; pathway cleared for subsequent submission.
• Strategic Importance: CEO André Larente highlighted regulatory approvals as a “significant catalyst for commercial growth and shareholder value.”

Notable Quotes

“Navigating the regulatory landscape for medical AI requires precision and expertise. Our team is fully focused on meeting the rigorous standards of Canada, the U.S., and Saudi Arabia,” – André Larente, CEO
“Securing these authorizations is a priority milestone that we believe will serve as a significant catalyst for commercial growth and shareholder value.” – André Larente, CEO